This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: F. Hoffmann-La Roche Ag, Health Research, Inc.. Active years: 2017.
Company Filing History:
1 out of 180 
1 out of 313 Years Active: 2017
Title: The Innovations of Evan Zynda
Introduction
Evan Zynda is an accomplished inventor based in Williamsville, NY (US). He has made significant contributions to the field of biotechnology, particularly in the area of inhibiting hypoxia-induced damage. His innovative work has the potential to impact various medical applications.
Latest Patents
Evan Zynda holds a patent for "Compositions and methods for inhibiting hypoxia-induced damage." This patent involves compositions and methods that utilize one or more agents to inhibit the expression of specific genes associated with hypoxia-related damage. The method includes introducing gene-inhibiting agents to cells, tissues, organs, or individuals to prevent the formation of such damage. Additionally, the patent encompasses kits that contain these agents along with instructions for their use.
Career Highlights
Throughout his career, Evan has worked with notable organizations, including Health Research, Inc. and F. Hoffmann-La Roche AG. His experience in these companies has allowed him to develop and refine his innovative ideas in the field of biotechnology.
Collaborations
Evan has collaborated with esteemed colleagues such as Eugene Kandel and Brigitte Schott. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Evan Zynda's contributions to the field of biotechnology through his innovative patent demonstrate his commitment to addressing critical medical challenges. His work in inhibiting hypoxia-induced damage showcases the potential for significant advancements in healthcare.